Negative predictive value of procalcitonin to rule out bacterial respiratory co-infection in critical covid-19 patients
Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: Procalcitonin (PCT) and C-Reactive Protein (CRP) are useful biomarkers to differentiate bacterial from viral or fungal infections, although the association between them and co-infection or mortality in COVID-19 remains unclear.
METHODS: The study represents a retrospective cohort study of patients admitted for COVID-19 pneumonia to 84 ICUs from ten countries between (March 2020-January 2021). Primary outcome was to determine whether PCT or CRP at admission could predict community-acquired bacterial respiratory co-infection (BC) and its added clinical value by determining the best discriminating cut-off values. Secondary outcome was to investigate its association with mortality. To evaluate the main outcome, a binary logistic regression was performed. The area under the curve evaluated diagnostic performance for BC prediction.
RESULTS: 4635 patients were included, 7.6% fulfilled BC diagnosis. PCT (0.25[IQR 0.1-0.7] versus 0.20[IQR 0.1-0.5]ng/mL, p<0.001) and CRP (14.8[IQR 8.2-23.8] versus 13.3 [7-21.7]mg/dL, p=0.01) were higher in BC group. Neither PCT nor CRP were independently associated with BC and both had a poor ability to predict BC (AUC for PCT 0.56, for CRP 0.54). Baseline values of PCT<0.3ng/mL, could be helpful to rule out BC (negative predictive value 91.1%) and PCT≥0.50ng/mL was associated with ICU mortality (OR 1.5,p<0.001).
CONCLUSIONS: These biomarkers at ICU admission led to a poor ability to predict BC among patients with COVID-19 pneumonia. Baseline values of PCT<0.3ng/mL may be useful to rule out BC, providing clinicians a valuable tool to guide antibiotic stewardship and allowing the unjustified overuse of antibiotics observed during the pandemic, additionally PCT≥0.50ng/mL might predict worsening outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
The Journal of infection - 85(2022), 4 vom: 15. Okt., Seite 374-381 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 13.09.2022 Date Revised 02.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2022.06.024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343017679 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343017679 | ||
| 003 | DE-627 | ||
| 005 | 20231226015435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2022.06.024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM343017679 | ||
| 035 | |a (NLM)35781017 | ||
| 035 | |a (PII)S0163-4453(22)00380-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carbonell, Raquel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Negative predictive value of procalcitonin to rule out bacterial respiratory co-infection in critical covid-19 patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2022 | ||
| 500 | |a Date Revised 02.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Procalcitonin (PCT) and C-Reactive Protein (CRP) are useful biomarkers to differentiate bacterial from viral or fungal infections, although the association between them and co-infection or mortality in COVID-19 remains unclear | ||
| 520 | |a METHODS: The study represents a retrospective cohort study of patients admitted for COVID-19 pneumonia to 84 ICUs from ten countries between (March 2020-January 2021). Primary outcome was to determine whether PCT or CRP at admission could predict community-acquired bacterial respiratory co-infection (BC) and its added clinical value by determining the best discriminating cut-off values. Secondary outcome was to investigate its association with mortality. To evaluate the main outcome, a binary logistic regression was performed. The area under the curve evaluated diagnostic performance for BC prediction | ||
| 520 | |a RESULTS: 4635 patients were included, 7.6% fulfilled BC diagnosis. PCT (0.25[IQR 0.1-0.7] versus 0.20[IQR 0.1-0.5]ng/mL, p<0.001) and CRP (14.8[IQR 8.2-23.8] versus 13.3 [7-21.7]mg/dL, p=0.01) were higher in BC group. Neither PCT nor CRP were independently associated with BC and both had a poor ability to predict BC (AUC for PCT 0.56, for CRP 0.54). Baseline values of PCT<0.3ng/mL, could be helpful to rule out BC (negative predictive value 91.1%) and PCT≥0.50ng/mL was associated with ICU mortality (OR 1.5,p<0.001) | ||
| 520 | |a CONCLUSIONS: These biomarkers at ICU admission led to a poor ability to predict BC among patients with COVID-19 pneumonia. Baseline values of PCT<0.3ng/mL may be useful to rule out BC, providing clinicians a valuable tool to guide antibiotic stewardship and allowing the unjustified overuse of antibiotics observed during the pandemic, additionally PCT≥0.50ng/mL might predict worsening outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Bacterial co-infection | |
| 650 | 4 | |a C-reactive protein | |
| 650 | 4 | |a Covid-19 pneumonia | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Procalcitonin | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Procalcitonin |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Urgelés, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Salgado, Melina |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Luis Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Fuentes, Yuli V |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano, Cristian C |e verfasserin |4 aut | |
| 700 | 1 | |a Caceres, Eder L |e verfasserin |4 aut | |
| 700 | 1 | |a Bodí, María |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Loeches, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Solé-Violán, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz, Emili |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Trefler, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Vallverdú, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Murcia, Josefa |e verfasserin |4 aut | |
| 700 | 1 | |a Albaya, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Loza, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Socias, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Ballesteros, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Papiol, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Viña, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Nieto, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Del, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lorente, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Badallo, Oihane |e verfasserin |4 aut | |
| 700 | 1 | |a Fraile, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Arméstar, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Estella, Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Abanses, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Sancho, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Guasch, Neus |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Gerard |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 SEMICYUC Working Group and the LIVEN-Covid-19 Investigators |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 85(2022), 4 vom: 15. Okt., Seite 374-381 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2022 |g number:4 |g day:15 |g month:10 |g pages:374-381 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2022.06.024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2022 |e 4 |b 15 |c 10 |h 374-381 | ||